Since the loss of BFL-1 increased the killing of M14 melanoma cells when combined with BH3 mimetic drugs that target MCL-1 and BCL-XL, we next tested the response of these cells to combination treatments that also include an inhibitor of MEK1/2, trametinib, or an inhibitor of ERK, ulixertinib, respectively (Fig. 1e). Here, BCL2L1 is linked to melanoma.